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See related research by Park et al., http://ccforum.com/content/18/6/640We greatly appreciated the recent research article by
Park and colleagues in Critical Care showing that pro-
calcitonin (PCT) is not superior to C-reactive protein
(CRP) as a marker for infection in renal impairment [1].
Additionally, we would like to comment on the validity
of CRP and PCT measurement during continuous renal
replacement therapy (CRRT). Both acute-phase proteins
are indeed effectively cleared by CRRT. CRP is predom-
inantly present as a monomer (mCRP) in the blood [2]
and is removed by all forms of CRRT because its molecu-
lar weight (22-25 kDa) lies below the cutoff permeability
limits of all classic dialysis membranes [3]. Most of the
PCT mass is easily eliminated by convection [4]. However,
although mCRP and PCT are adequately filtered, substan-
tial amounts of both are adsorbed on the dialysis mem-
brane [3, 4]. Therein lies a clinically relevant but poorly
recognized problem! In fact, highly adsorptive dialysis
membranes are increasingly applied to CRRT in many in-
tensive care units worldwide. The use of such membranes
will inherently accentuate mCRP and PCT removal. As a
result, plasma levels of both biomarkers risk becoming
falsely low during CRRT and thereby losing all potential to
help clinicians diagnose or evaluate infection. The recently
introduced sepsis biomarkers brain natriuretic peptide
and N-terminal pro-brain natriuretic peptide have been
proclaimed to be superior to CRP and PCT, but whether
they perform better under CRRT is doubtful because their
molecular weights (3.5 and 8.5 kDa, respectively) already
predict highly effective clearance by both high- and low-
flux membranes [5].* Correspondence: patrick.honore@az.vub.ac.be
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